Rohto’s Cirrhosis Cell Therapy Finds Japan Partner In Shionogi

In a sign of continued corporate interest in the regenerative and cell therapy area in Japan, Shionogi has acquired rights in this market to a novel cirrhosis treatment being developed by Rohto.